A comprehensive analysis of over 21,000 women has illuminated a potential link between the use of estrogen-only hormone therapy in later life and a diminished presence of Alzheimer’s disease hallmarks in the brain. Published in the esteemed medical journal Neurology on August 12, 2026, the research, conducted by a team from Stanford Medicine, suggests a notable association, though researchers are careful to emphasize that correlation does not equate to causation. The findings offer a nuanced perspective on the long-term impact of hormone replacement therapy on cognitive health in postmenopausal women.
The study’s lead author, Dr. Jennifer Bruno, a researcher at Stanford Medicine, articulated the significance and limitations of the findings. "While these results contribute to our understanding of the intricate relationship between hormone therapy and various indicators of dementia, further rigorous investigation is imperative before any definitive recommendations can be made to women concerning their use of these therapies for brain health," Dr. Bruno stated. She further elaborated on the temporal context of the research: "This investigation reviewed the medical histories of women who engaged in hormone therapy several decades ago. The specific timing and modalities of treatment differed considerably from contemporary medical practices, rendering the findings informative but not directly transferable to current therapeutic standards." This cautionary note underscores the evolving landscape of hormone therapy and its administration.
The research meticulously examined data from two substantial cohorts, encompassing a total of 21,462 female participants who underwent clinical evaluations during their lifetimes. Within these extensive datasets, a significant subset of individuals underwent advanced neuroimaging or biomarker assessments while alive. Specifically, 728 participants in one cohort received brain scans or biomarker testing. In the second, larger cohort, 2,959 participants were subjected to post-mortem autopsies, conducted on average at the age of 82, allowing for a detailed examination of brain tissue for pathological evidence of Alzheimer’s disease. The participants in both datasets were monitored for an average duration of three to five years, commencing at an average age of 71.
Of the total study population, a discernible portion, 1,953 women, reported the use of hormone therapy, while the vast majority, 19,509 women, did not. A key characteristic of the hormone therapy users was that they typically initiated treatment after the age of 70, a detail that differentiates their usage patterns from current clinical guidelines.
Crucially, the scope of this particular analysis was confined exclusively to estrogen-only hormone therapy. This focus stems from prior research that indicated a potential increase in dementia risk associated with combined hormone therapy, which includes both estrogen and progestin. Current medical consensus dictates that estrogen-only therapy is generally prescribed to women who have undergone a hysterectomy, thereby mitigating the risk of endometrial cancer, a known complication of unopposed estrogen.
The examination of post-mortem brain tissue yielded compelling results. Among the women whose brains were analyzed, those who had previously utilized hormone therapy exhibited a reduced likelihood of displaying the characteristic pathological markers of Alzheimer’s disease. Researchers meticulously assessed three principal indicators associated with Alzheimer’s: amyloid-beta plaques, tau tangles, and neuritic plaques. Neuritic plaques are essentially amyloid plaques that are surrounded by degenerated nerve cells, signifying advanced neuropathology. These indicators were then aggregated into a composite score to quantify the extent of Alzheimer’s-related pathology present in the brain.
The autopsy findings revealed that 18% of women who had used hormone therapy showed no discernible signs of Alzheimer’s disease, a stark contrast to the 10% observed in the group that had not undergone hormone therapy. Conversely, at the more severe end of the spectrum, only 40% of hormone therapy users presented with all three cardinal signs of Alzheimer’s disease, compared to a significantly higher 51% among non-users.
Even after meticulously accounting for a range of confounding variables, including age, educational attainment, genetic predispositions, racial background, and the presence of hypertension, the association between hormone therapy use and reduced Alzheimer’s pathology remained statistically significant. Hormone therapy use was linked to a 35% lower probability of exhibiting signs of Alzheimer’s disease at autopsy.
Further bolstering these findings, a parallel analysis of biomarker data collected during the participants’ lives provided corroborating evidence. Women who had engaged in hormone therapy demonstrated amyloid biomarker levels in their blood and cerebrospinal fluid that were indicative of less amyloid accumulation within the brain when contrasted with women who had not used hormone therapy. Elevated levels of amyloid-beta protein in peripheral fluids, such as blood and spinal fluid, can serve as an indirect marker, suggesting that less of this protein is being deposited in the brain in the form of amyloid plaques.
Moreover, the study indicated that hormone therapy use was associated with a 39% reduction in the odds of receiving a clinical diagnosis of dementia. This translated into a lower incidence of reported memory impairments and declines in the ability to perform daily functional tasks among hormone therapy users.
However, a critical caveat to these findings lies in the distinct patterns of hormone therapy use observed in the study population compared to contemporary clinical practice. Dr. Bruno highlighted that the average age at which participants in the study began hormone therapy was around 70. In contrast, current standard medical protocols generally recommend initiating hormone therapy between the late 40s and early 50s, with a typical cessation of treatment before the age of 60. This divergence in treatment timing and duration is a crucial factor that may influence the generalizability of the results to today’s patient population.
"Notwithstanding these inherent limitations," Dr. Bruno concluded, "our findings offer compelling evidence for an association between the utilization of estrogen-only hormone therapy during later life and more favorable outcomes in terms of dementia prevalence and brain health markers." The research was generously supported by a grant from the National Institute on Aging, underscoring the importance of this line of inquiry in understanding age-related cognitive decline and potential therapeutic interventions.
About the Author
